|
Apr 10
|
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
|
|
Apr 10
|
Nurix Therapeutics Inc (NRIX) Misses Earnings Predictions But Shows Revenue Growth in Q1 Fiscal 2024
|
|
Apr 10
|
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
|
|
Apr 10
|
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
|
|
Apr 9
|
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
|
|
Apr 9
|
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
|
|
Apr 4
|
Vanda (VNDA) Soars 29.2%: Is Further Upside Left in the Stock?
|
|
Apr 2
|
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
|
|
Mar 25
|
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
|
|
Mar 20
|
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
|
|
Mar 11
|
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
|
|
Mar 6
|
Nurix Therapeutics to Participate in Upcoming Investor Conferences
|
|
Mar 5
|
Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting
|
|
Feb 23
|
Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?
|
|
Feb 6
|
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Feb 1
|
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader
|
|
Feb 1
|
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
|
|
Jan 16
|
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL
|
|
Jan 9
|
Apellis Pharmaceuticals, Inc. (APLS) Soars 14.7%: Is Further Upside Left in the Stock?
|
|
Dec 21
|
CFO Houte Van Sells 10,906 Shares of Nurix Therapeutics Inc
|